3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
18
Breast Neoplasms
12
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Sleep Wake Disorders
1
Skin Diseases
1
Salivary Gland Adenoma, Pleomorphic
1
Osteoporosis
1
Leiomyoma
1
Hemorrhage
1
Fatigue
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Breast Neoplasms, Male
1
Advanced Breast Cancer
1
Interventions
exemestane
4
Tamoxifen
3
Paclitaxel
3
Letrozole
3
Goserelin
3
Cyclophosphamide
3
pegfilgrastim
2
Radiotherapy
2
Pyridoxine
2
Leuprolide
2
Fluorouracil
2
Epirubicin
2
Capecitabine
2
Bevacizumab
2
Anastrozole
2
trastuzumab biosimilar HLX02
1
ribociclib
1
elacestrant
1
Zoledronic Acid
1
Trastuzumab
1
Taxes
1
Radiosurgery
1
Prochlorperazine
1
Palonosetron
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Neoadjuvant Therapy
1
Mometasone Furoate
1
Methotrexate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Breast Neoplasms, Male
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT01638247
2018-09-19
MALE
GBG Forschungs GmbH
Phase 3
Completed
56 enrolled